 Connection
Terry Fry to Sialic Acid Binding Ig-like Lectin 2
This is a "connection" page, showing publications Terry Fry has written about Sialic Acid Binding Ig-like Lectin 2.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.297 |
|
|
|
-
DeGolier KR, Pham-Danis C, Burciaga SD, Walsh ZH, Brzezinski C, Novak AJ, Leach L, Cimons J, Li W, Zhongyu Z, Dimitrov D, Scott-Browne JP, Kohler ME, Fry TJ. Rational redesign of antigen binding domain improves in vivo efficacy of the CD22-CAR. Mol Ther. 2026 Apr 01; 34(4):2175-2188.
Score: 0.931
-
Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, Shalabi H, Fountaine TJ, Shern JF, Majzner RG, Stroncek DF, Sabatino M, Feng Y, Dimitrov DS, Zhang L, Nguyen S, Qin H, Dropulic B, Lee DW, Mackall CL. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018 01; 24(1):20-28.
Score: 0.531
-
Silbert SK, Gava F, Yates B, Rankin AW, Rocco JM, Shao L, Dreyzin A, Cai Y, Lamplugh C, Han KL, Prochazkova M, Little L, Foley T, Sankaran H, Martin K, Garces P, Jin P, Chien CD, Taylor N, Fry TJ, Yuan CM, Wang HW, Stroncek DF, Highfill SL, Shalabi H, Shah NN. CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results. J Immunother Cancer. 2026 Jun 05; 14(6).
Score: 0.240
-
Dreyzin A, Yates B, Shalabi H, Silbert SK, Wang HW, Yuan CM, Hoang CN, Culbert AA, Gava F, Nair MS, Giordani VM, Little L, Foley T, Nussenblatt V, Fry TJ, Stroncek DF, Highfill SL, Shah NN. Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia. Blood Adv. 2026 Mar 10; 10(5):1700-1712.
Score: 0.236
-
Dreyzin A, Kramer AM, Yates B, Wang HW, Sahaf B, Yuan C, Klysz D, Tunuguntla R, Ehlinger Z, Reitberg S, Adebola S, Su A, Ebina-Shibuya R, Jia D, Achar S, Patil S, Martin K, Jeyakumar N, Davis KL, Fry T, Mackall CL, Taylor N, Altan-Bonnet G, Highfill S, Feldman S, Stroncek DF, Chien C, Schultz LM, Frank MJ, Muffly LS, Shalabi H, Ramakrishna S, Shah NN. Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies. Cytotherapy. 2026 Mar; 28(3):101990.
Score: 0.229
-
Shah NN, Fry TJ. The CD19neg needle in the haystack. Blood. 2022 07 07; 140(1):4-6.
Score: 0.183
-
Lichtenstein DA, Schischlik F, Shao L, Steinberg SM, Yates B, Wang HW, Wang Y, Inglefield J, Dulau-Florea A, Ceppi F, Hermida LC, Stringaris K, Dunham K, Homan P, Jailwala P, Mirazee J, Robinson W, Chisholm KM, Yuan C, Stetler-Stevenson M, Ombrello AK, Jin J, Fry TJ, Taylor N, Highfill SL, Jin P, Gardner RA, Shalabi H, Ruppin E, Stroncek DF, Shah NN. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood. 2021 12 16; 138(24):2469-2484.
Score: 0.176
-
Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH, Frank MJ, Shiraz P, Sahaf B, Craig J, Iglesias M, Younes S, Natkunam Y, Ozawa MG, Yang E, Tamaresis J, Chinnasamy H, Ehlinger Z, Reynolds W, Lynn R, Rotiroti MC, Gkitsas N, Arai S, Johnston L, Lowsky R, Majzner RG, Meyer E, Negrin RS, Rezvani AR, Sidana S, Shizuru J, Weng WK, Mullins C, Jacob A, Kirsch I, Bazzano M, Zhou J, Mackay S, Bornheimer SJ, Schultz L, Ramakrishna S, Davis KL, Kong KA, Shah NN, Qin H, Fry T, Feldman S, Mackall CL, Miklos DB. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med. 2021 08; 27(8):1419-1431.
Score: 0.171
-
Shah NN, Highfill SL, Shalabi H, Yates B, Jin J, Wolters PL, Ombrello A, Steinberg SM, Martin S, Delbrook C, Hoffman L, Little L, Ponduri A, Qin H, Qureshi H, Dulau-Florea A, Salem D, Wang HW, Yuan C, Stetler-Stevenson M, Panch S, Tran M, Mackall CL, Stroncek DF, Fry TJ. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. J Clin Oncol. 2020 06 10; 38(17):1938-1950.
Score: 0.157
-
Shah NN, Qin H, Yates B, Su L, Shalabi H, Raffeld M, Ahlman MA, Stetler-Stevenson M, Yuan C, Guo S, Liu S, Hughes SH, Fry TJ, Wu X. Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. Blood Adv. 2019 08 13; 3(15):2317-2322.
Score: 0.150
-
Shalabi H, Wolters PL, Martin S, Toledo-Tamula MA, Roderick MC, Struemph K, Kane E, Yates B, Delbrook C, Mackall CL, Lee DW, Fry TJ, Shah NN. Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy. J Immunother. 2018 Sep; 41(7):350-358.
Score: 0.140
-
Fry TJ, Mackall CL. T-cell adoptive immunotherapy for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2013; 2013:348-53.
Score: 0.095
-
Rankin AW, Pham-Danis C, Novak AJ, Danis E, Fry TJ, Kohler ME. Increased NFAT activity with dual CAR stimulation in CD19xCD22 CAR T-cells is associated with decreased exhaustion and improved survival. J Immunother Cancer. 2025 Nov 13; 13(11).
Score: 0.058
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|